Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20275818 | 0.80 | SLC6A2 (0.49) | HTR2ACYP1A2OPRM1SLC6A2SLC6A3 | |
| SCHEMBL10648670 | 0.77 | SLC6A2 (0.38) | HTR2ACYP1A2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL977558 | 0.77 | HTR2A (0.47) | HTR2AOPRM1SLC6A2SLC6A3CHRNB2 | |
| SCHEMBL11745922 | 0.76 | SLC6A2 (0.38) | CYP1A2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3457864 | 0.75 | SLC6A2 (0.41) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL27794398 | 0.74 | HTR2A (0.44) | HTR2AOPRM1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1334863 | 0.74 | HTR2A (0.44) | HTR2ACYP1A2OPRM1SLC6A2SLC6A3 | |
| SCHEMBL136222 | 0.74 | HTR2A (0.44) | HTR2AOPRM1SLC6A2SLC6A3CHRNB2 | |
| SCHEMBL10880855 | 0.74 | HTR2A (0.44) | HTR2AOPRM1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL29240149 | 0.74 | HTR2A (0.41) | HTR2AOPRM1SLC6A2SLC6A3CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170958-B | Preparation method of hydroxybenzomorph | 浙江鼎龙科技股份有限公司 | 2021-08-10 | — | — | CN | claimed |
| CN-111170958-A | Preparation method of hydroxybenzomorph | 浙江鼎龙科技有限公司 | 2020-05-19 | — | — | CN | claimed |
| US-4576944-A | STIMULANTS, ANTIDEPRESSANTS | LABORATOIRE L. LAFON (FR) | 1986-03-18 | — | — | US | claimed |
| CN-114942280-A | Method for content determination and mass spectrum confirmation of 12 hair dyes in cosmetics | 上海市食品药品检验研究院 | 2022-08-26 | — | — | CN | disclosed |
| CN-111170958-B | Preparation method of hydroxybenzomorph | 浙江鼎龙科技股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-111170958-B | Preparation method of hydroxybenzomorph | 浙江鼎龙科技股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-111170958-A | Preparation method of hydroxybenzomorph | 浙江鼎龙科技有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-111170958-A | Preparation method of hydroxybenzomorph | 浙江鼎龙科技有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-109134297-A | One inter-species di alkylamino group phenol is continuously synthesizing to method | 江苏迪安化工有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-109134281-A | Between di alkylamino group phenol synthetic method | 浙江山峪科技股份有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-109020827-A | The synthetic method of one inter-species di alkylamino group phenol | 浙江山峪科技股份有限公司 | 2018-12-18 | — | — | CN | disclosed |
| US-20030100479-A1 | Gene polymorphisms and response to treatment | DOW DAVID J (GB) | 2003-05-29 | — | — | US | disclosed |
| WO-2003018843-A1 | GENE POLYMORPHISMS AND RESPONSE TO TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20030008832-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | disclosed |
| CN-1074413-C | Novel benzimidazole derivatives having CGMP-phosphodisterase inhibiting activity | OTSUKA PHARMA CO LTD (JP) | 2001-11-07 | — | — | CN | disclosed |
| EP-0779887-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODIESTERASE INHIBITING ACTIVITY | OTSUKA PHARMA CO LTD (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5998437-A | ARTERIOSCLEROSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| CN-1158129-A | Novel benzimidazole derivatives having CGMP-phosphodisterase inhibiting activity | OTSUKA PHARMA CO LTD (JP) | 1997-08-27 | — | — | CN | disclosed |
| EP-0779887-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| WO-1997003070-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100479-A1 | Gene polymorphisms and response to treatment | SLC6A2, SLC6A4, SLC6A3 | HTR2A 23/4885CYP1A2 504/4885OPRM1 51/4885 |
| US-20030008832-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | HTR2A 4451/4885CYP1A2 2018/4885OPRM1 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.